Pages that link to "Q26770823"

The following pages link to Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis (Q26770823):

Displayed 11 items.

• Investigational drugs for treating agitation in persons with dementia (Q30250076) ‎ (← links)
• Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? (Q38748394) ‎ (← links)
• Building smart cannabis policy from the science up. (Q39131734) ‎ (← links)
• Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity (Q39178828) ‎ (← links)
• Trends in GPCR drug discovery: new agents, targets and indications. (Q47597808) ‎ (← links)
• [What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity]. (Q50074100) ‎ (← links)
• Cannabis-based medicines for chronic neuropathic pain in adults (Q56815074) ‎ (← links)
• Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro (Q89679208) ‎ (← links)
• Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial (Q90567163) ‎ (← links)
• Opportunities for cannabis in supportive care in cancer (Q92627340) ‎ (← links)
• Immune Responses Regulated by Cannabidiol (Q93167508) ‎ (← links)